A Phase 2 Study of E6005 in Patients With Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

November 30, 2012

Study Completion Date

January 31, 2013

Conditions
Atopic Dermatitis
Interventions
DRUG

E6005

0.0% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.

DRUG

E6005 ointment (vehicle)

0.2% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.

Trial Locations (10)

Unknown

Nagoya

Urayasu-shi

Fukuoka

Asahikawa-shi

Sapporo

Yokohama

Adachi-ku

Chiyoda-ku

Minato-ku

Shinagawa-ku

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT01461941 - A Phase 2 Study of E6005 in Patients With Atopic Dermatitis | Biotech Hunter | Biotech Hunter